For the 15th Annual Global Forum, we re-released some of the most well received industry content from 2016's event.
Take a look at our Global Forum Content Pack or request an emailed copy that includes:
- In-depth report on "Standardization and Risk Management in the Cold Chain"
- Best Practice Guidebook for "Packaging Design & Qualification in Temperature Controlled Logistics"
- Global Mastery eBook featuring interviews with Eli Lilly, Amgen, McKesson, Novartis LatAm and many more
Email email@example.com to request an emailed copy.
- Examine the full scope of DSCSA requirements and top international serialization deadlines that are looming How can logistics professionals support serialization teams past the 2017 deadline
- What application does serialization technology have for temperature monitoring? Can they work in tandem?
- Predicting how a post-serialized world will affect the pharma supply chain
Presentation by Matt Sample Sr. Director, Secure Supply Chain AmerisourceBergen Corporation
In meeting the growth ahead for clinical trials there must be a focus on efficiency as their supply already suffers from major issues with wastage levels. This is lack of control is problematic with the rising public scrutiny on spending by pharmaceutical companies.
Forecasting and demand planning
When sites are under supplied, sponsors may be forced to halt enrolment or even freeze patient treatments. This could have a large influence on the outcomes of a trial. Due to a range of factors, study design, patient enrolment, quantity of sites, site location, that can suddenly change the level of supplies needed for a trial to run, supply managers reduce the risk of stock outs by supplying a surplus of medicine. This in many cases spills over to become overage – when the investigational medicines have to be wasted at the end of a trial or hit their expiry dates before consumption.
Though life sciences companies see value across the full supply chain, it’s the last mile that matters the most to the customer. When customers can’t get what they want when they want it due to product loss, theft, spoilage, counterfeiting or other disruptions, it can be incredibly damaging to a company’s brand and bottom line.
With this in mind, we surveyed 150+ pharma logistics leaders to learn more about the key challenges, solutions and trends impacting the last mile of the life sciences supply chain. Highlights include:
- Analysis of what causes the most last mile disruptions and how firms are addressing these issues
- An overview of our respondents top strategic priorities
- Facts & figures that outline where cold chain leaders are looking to invest on 2018 & 2019
From Production to Patients: An In-Depth Report on Optimizing the Last Mile of the Life Sciences Supply Chain
How are leading-edge pharma firms optimizing the last mile of the supply chain? Find out in our most recent report!
This whitepapers covers the latest pharmaceutical logistics regulatory developments around the globe related to FMD, MHRA, ICH Q12, PACMP, GMP, DSCSA and more! Designed specifically to keep you up to date with key developments that we believe with shape the compliance agenda over the next year, key developments that you will need to tune in for! Highlights include:
- GMP inspections international collaboration efforts
- Supply Chain Security and Traceability – GPS
- EMA regulations
- Points to remember for your next GDP inspection
- The latest on Human Drug Compounding Outsourcing Facilities regulations
- An analysis of ICH Q12 concepts
- The cost of Brexit and the road forward
- An overview of EU's recently published report detailing the implementation of the Falsified Medicines Directive (FMD)
Plus! Commentary by 2018 Cold Chain Global Forum speakers:
- Rafik Bishara, Ph.D, former Director QKMTS, Eli Lilly and Company
- Ajay Pazhayattil, Former Associate Director, TOPV Apotex Inc.
Pharma is one of the most conservative industries –namely due to the fact that its products are high risk – very influential to the health, well-being and survival of their consumers. Regulations must be met to ensure that medicine quality and patient safety is protected. Therefore any changes, be it to product or process, need to be controlled to ensure that these vital elements are not in anyway jeopardized.
In the latest article by Pharma IQ,we uncover:
- How to identify and overcome common obstacles to change management in pharma
- Establishing standardized packaging vendor qualification requirements
- Why collaboration and intelligence sharing between drug manufacturers could drastically improve the landscape for the general market.
- And more!
Features insights by:
- Guy Hoskens, Clinical Supply Chain Logistics Expert, Janssen, Pharmaceutical
- Tonino Antonetti, Executive Director, Regulatory Affairs, Quality Management, Safety & Health, Roche Diagnostics
- Craig Vermeyen, Senior Manager, Packaging Engineer, Kite Pharma
To receive a copy of this article via email, write us at firstname.lastname@example.org with "16CCGF Content Request: Change & Collaboration in Pharma Logistics" in the subject line.
Experts have asserted that despite recent developments, pharmaceutical supply chains are still far from reaching their full technological potential. However, Blockchain holds significant promise to advance the digital strength of medicine supply. In this whitepaper, we explore:
- What is blockchain and how can it be applied to cold chain?
- Who in life sciences is currently using blockchain and for what?
- How will the emergence of blockchain impact the industry over the next decade?
Plus! We provide an overview of potential use cases for block chain such as:
- Leveraging R&D data for collaborative research
- Dynamic pricing managed for raw materials
- Compliance and quality tracking
- Pharmacovigilance reporting
- Temperature control
- Temperature monitoring and control